Both AstraZeneca and Bristol Myers Squibb reportedly did not return requests for comment to either news outlet. On Friday, the two companies carried a combined market capitalization of nearly $400 billion—AstraZeneca at approximately $264 billion and Bristol Myers Squibb at $133 billion. AstraZeneca shares dropped as much as 7% Monday—the second-biggest decline on the FTSE 100—while Bristol Myers gained roughly 6% in US premarket trading. Bristol Myers sourced 69% of revenues from the US last quarter. RBC Capital Markets analysts noted that Bristol Myers has major trial readouts ahead for its blood thinner milvexian and schizophrenia drug Cobenfy, making the fit difficult to assess.